Full Text View
Tabular View
Study Results
Related Studies
Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream
This study has been completed.
Study NCT00189306   Information provided by Graceway Pharmaceuticals, LLC

First Received on September 13, 2005.   Last Updated on August 5, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Superficial Basal Cell Carcinoma
Additional conditions recognized in this trial
Carcinoma
Carcinoma, Basal Cell
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Basal Cell
Neoplasms, Glandular and Epithelial
Interventions listed in this trial
Imiquimod 5% cream
Additional drug interventions recognized in this trial
Imiquimod
More general drug interventions related to this trial
Adjuvants, Immunologic
Antineoplastic Agents
Immunologic Factors
Interferon Inducers
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Graceway Pharmaceuticals, LLC


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services